Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Harrow Health Inc is a drug manufacturers-specialty & generic business based in the US. Harrow Health shares (HROW) are listed on the NASDAQ and all prices are listed in US Dollars. Harrow Health employs 182 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $7.14 |
|---|---|
| 52-week range | $5.40 - $12.99 |
| 50-day moving average | $6.70 |
| 200-day moving average | $8.20 |
| Wall St. target price | $17.38 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-0.78 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.14 from 2022-07-01
| 1 week (2022-06-27) | -3.25% |
|---|---|
| 1 month (2022-05-31) | -1.24% |
| 3 months (2022-03-31) | N/A |
| 6 months (2021-12-31) | N/A |
| 1 year (2021-07-02) | -22.39% |
|---|---|
| 2 years (2020-07-02) | 35.23% |
| 3 years (2019-07-03) | 7.76 |
| 5 years (2017-07-03) | 119.02% |
Valuing Harrow Health stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Harrow Health's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Harrow Health's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 million.
The EBITDA is a measure of a Harrow Health's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $79.2 million |
|---|---|
| Operating margin TTM | 3.22% |
| Gross profit TTM | $54.3 million |
| Return on assets TTM | 2.07% |
| Return on equity TTM | -109.89% |
| Profit margin | -26.1% |
| Book value | $0.37 |
| Market capitalisation | $193 million |
TTM: trailing 12 months
We're not expecting Harrow Health to pay a dividend over the next 12 months.
Harrow Health's shares were split on a 1:5 basis on 7 February 2013. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Harrow Health shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Harrow Health shares which in turn could have impacted Harrow Health's share price.
Over the last 12 months, Harrow Health's shares have ranged in value from as little as $5.4 up to $12.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Harrow Health's is 0.9038. This would suggest that Harrow Health's shares are less volatile than average (for this exchange).
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc. , a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc. , a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc. , a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.